ATE444309T1 - Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper - Google Patents

Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper

Info

Publication number
ATE444309T1
ATE444309T1 AT01957479T AT01957479T ATE444309T1 AT E444309 T1 ATE444309 T1 AT E444309T1 AT 01957479 T AT01957479 T AT 01957479T AT 01957479 T AT01957479 T AT 01957479T AT E444309 T1 ATE444309 T1 AT E444309T1
Authority
AT
Austria
Prior art keywords
immunotherapy
myelocytic leukemia
antibodies
naked anti
cronic
Prior art date
Application number
AT01957479T
Other languages
English (en)
Inventor
David Goldenberg
Hans Hansen
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of ATE444309T1 publication Critical patent/ATE444309T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01957479T 2000-08-08 2001-08-08 Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper ATE444309T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22369800P 2000-08-08 2000-08-08
PCT/US2001/024691 WO2002012347A1 (en) 2000-08-08 2001-08-08 Immunotherapy for chronic myelocytic leukemia

Publications (1)

Publication Number Publication Date
ATE444309T1 true ATE444309T1 (de) 2009-10-15

Family

ID=22837639

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01957479T ATE444309T1 (de) 2000-08-08 2001-08-08 Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper

Country Status (10)

Country Link
US (2) US6759045B2 (de)
EP (1) EP1309627B1 (de)
JP (1) JP3888971B2 (de)
CN (1) CN1468259A (de)
AT (1) ATE444309T1 (de)
AU (1) AU7921701A (de)
CA (1) CA2418014C (de)
DE (1) DE60140063D1 (de)
DK (1) DK1309627T3 (de)
WO (1) WO2002012347A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
AU2001290801A1 (en) * 2000-09-12 2002-03-26 Zycos Inc. Peptide epitopes recognized by antigen specific cd4+ t lymphocytes
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2002360525A1 (en) * 2001-12-06 2003-06-23 University Of Florida Targeting leukemia cells
US20050063947A1 (en) * 2002-03-27 2005-03-24 Patrick Hwu Method for treating cancer in humans
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
WO2004043461A1 (en) * 2002-11-06 2004-05-27 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
HUE026914T2 (en) 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
WO2005000894A2 (en) * 2003-06-25 2005-01-06 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
US7939058B2 (en) * 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
DE602004029934D1 (de) * 2003-12-04 2010-12-16 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
US8038996B2 (en) * 2004-03-27 2011-10-18 University Of Arizona Composition and method for cancer treatment
US7977320B2 (en) * 2004-10-29 2011-07-12 The Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
US20060234959A1 (en) * 2005-04-14 2006-10-19 Advanced Photodynamic Technologies, Inc. Photodynamic therapy utilizing multiple duty cycle light modulation
US20060257317A1 (en) * 2005-05-04 2006-11-16 Duke University Combination therapy in the treatment of cancer
US9072797B2 (en) 2005-11-30 2015-07-07 Therapharm Gmbh Immunoconjugate for human CD66 for the treatment of multiple myeloma and other haematological malignancies
WO2008029271A2 (en) 2006-02-27 2008-03-13 Gal Markel Ceacam based antibacterial agents
WO2007119808A1 (ja) * 2006-04-13 2007-10-25 Medical And Biological Laboratories Co., Ltd. 融合パートナー細胞
AU2007317333A1 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
ES2738310T3 (es) 2012-10-12 2020-01-21 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
AU2014244245C1 (en) 2013-03-13 2018-04-19 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
US11110179B2 (en) 2016-06-03 2021-09-07 Seagen Inc. Combination of CD33 antibody drug conjugates with chemotherapeutic agents
EP3469001A4 (de) 2016-06-09 2020-05-06 Seattle Genetics, Inc. Kombinationen von pbd-basierten antikörper-arzneimittel-konjugaten mit flt3-inhibitoren
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
DK2255800T3 (da) * 1997-11-10 2013-02-04 Sloan Kettering Inst Cancer Arsentrioxid til anvendelse ved behandling af leukæmi
US6491917B1 (en) 1998-07-31 2002-12-10 Stemcell Technologies Inc. Antibody composition for debulking blood and bone marrow samples from CML patients

Also Published As

Publication number Publication date
JP3888971B2 (ja) 2007-03-07
DK1309627T3 (da) 2009-12-21
EP1309627A1 (de) 2003-05-14
CA2418014C (en) 2014-01-21
US20020022031A1 (en) 2002-02-21
US6759045B2 (en) 2004-07-06
WO2002012347A1 (en) 2002-02-14
AU2001279217C1 (en) 2002-02-18
US7323168B2 (en) 2008-01-29
CN1468259A (zh) 2004-01-14
AU7921701A (en) 2002-02-18
CA2418014A1 (en) 2002-02-14
US20040213796A1 (en) 2004-10-28
EP1309627B1 (de) 2009-09-30
DE60140063D1 (de) 2009-11-12
JP2004505994A (ja) 2004-02-26

Similar Documents

Publication Publication Date Title
DE60140063D1 (de) Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper
MXPA05005726A (es) Metodos y composiciones para inducir apoptosis en celulas de cancer.
MA42999B1 (fr) Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë
MX2021007350A (es) Terapia combinada de cd70 y venetoclax, un inhibidor de bcl-2, para tratar la leucemia mieloide aguda.
CL2007001624A1 (es) Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular.
CL2012000519A1 (es) Uso de un anticuerpo aislado o fragmento de enlace antígeno del mismo que comprende una región variable de cadena ligera y una de cadena pesada (sec nº38 y nº40) útil en el tratamiento y prevención de carcinoma de células escamosas en un mamífero (div. sol. 3615-07).
TW200612918A (en) Lonidamine analogs
IL184617A (en) Antibody against dr5 that includes mutations in the heavy and light chain of the full-length antibody 16e2 and various aspects related to this antibody
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
MA43000B1 (fr) Polythérapie pour le traitement de tumeurs malignes
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
AR023616A1 (es) Preparaciones combinadas que comprenden derivados de antraciclina
BR0306820A (pt) Uso de inibidores cox-2 em combinação com agentes antivirais para o tratamento de infecções de papilomavìrus
HRPK20041072B3 (hr) Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
WO2008112129A3 (en) Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
MXPA02007899A (es) Citoquinas modificadas para utilizarse en terapia de cancer.
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
WO2008066854A3 (en) Methods and compositions for inducing apoptosis in cancer cells
MY157366A (en) Therapies and compositions comprising cathepsin s antibodies
AU2021334165A8 (en) Method of treatment of patients having reduced sensitivity to a BCL-2 inhibitor
ATE509630T1 (de) Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern
GT200000194A (es) Quimioterapia de combinacion.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties